Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics (AKRO)
:AKRO
AKRO Stock Chart & Stats
$54.65
-$0.52(-1.95%)
At close: 4:00 PM EST
$54.65
-$0.52(-1.95%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume136.04K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise Value$3.16B
Total Cash (Recent Filing)$737.83M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 12, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)2.49
Price to Sales (P/S)0.00
P/FCF Ratio-8.12
Enterprise Value/Market Cap10.00T>
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionNovo Nordisk aims to acquire AKRO for up to $5.2B, signaling Big Pharma's high interest in MASH and FGF21.
Clinical DataEfruxifermin (EFX) has shown best-in-class efficacy in F4 cirrhosis and robust efficacy in F2-F3 pre-cirrhotic MASH.
Shareholder BenefitsShareholders will receive $54 per share, with an additional potential milestone payment of $6 per share upon EFX full U.S. approval.
Bears Say
Price TargetThe price target for AKRO has been decreased based on the deal terms, suggesting a reassessment of the company's valuation.
Product DevelopmentNovo discontinued development of its own FGF21 analog, zalfermin, after disappointing Phase II data in F2-4 MASH.
Stock RatingThe stock rating has been downgraded to Hold from Buy due to the acquisition.
Akero Therapeutics News
AKRO FAQ
What was Akero Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Akero Therapeutics’s market cap?
Currently, no data Available
When is Akero Therapeutics’s upcoming earnings report date?
Akero Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 82 days.
How were Akero Therapeutics’s earnings last quarter?
Akero Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.954 by $0.054.
Is Akero Therapeutics overvalued?
According to Wall Street analysts Akero Therapeutics’s price is currently Overvalued.
Does Akero Therapeutics pay dividends?
Akero Therapeutics does not currently pay dividends.
What is Akero Therapeutics’s EPS estimate?
Akero Therapeutics’s EPS estimate is -0.92.
How many shares outstanding does Akero Therapeutics have?
Currently, no data Available
What happened to Akero Therapeutics’s price movement after its last earnings report?
Akero Therapeutics reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.954. Following the earnings report the stock price went up 0.092%.
Which hedge fund is a major shareholder of Akero Therapeutics?
Currently, no hedge funds are holding shares in AKRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
― Insiders
58.38% Mutual Funds
― Other Institutional Investors
27.19% Public Companies and
Individual Investors